Nevro Corp (NYSE:NVRO) has received an average rating of “Buy” from the eleven analysts that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $86.10.

A number of equities analysts have weighed in on NVRO shares. Wells Fargo & Co lifted their price objective on Nevro from $86.00 to $105.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. JMP Securities lifted their price objective on Nevro to $115.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Bank of America raised their target price on Nevro from $70.00 to $74.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Leerink Swann set a $98.00 target price on Nevro and gave the company a “buy” rating in a research report on Friday, August 23rd. Finally, Zacks Investment Research upgraded Nevro from a “sell” rating to a “hold” rating and set a $67.00 target price on the stock in a research report on Tuesday, August 13th.

Shares of NYSE NVRO traded down $0.01 during trading on Monday, reaching $111.77. 347,112 shares of the company traded hands, compared to its average volume of 516,769. The firm’s fifty day simple moving average is $96.44 and its 200 day simple moving average is $77.94. The stock has a market cap of $3.47 billion, a P/E ratio of -68.15 and a beta of 0.30. Nevro has a 12-month low of $34.75 and a 12-month high of $114.22. The company has a current ratio of 5.87, a quick ratio of 4.54 and a debt-to-equity ratio of 0.91.

Nevro (NYSE:NVRO) last released its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.58) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.85) by $0.27. The business had revenue of $100.16 million during the quarter, compared to analyst estimates of $92.27 million. Nevro had a negative return on equity of 46.35% and a negative net margin of 25.94%. The company’s revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.37) EPS. As a group, research analysts expect that Nevro will post -3.74 EPS for the current year.

In related news, VP Doug Alleavitch sold 1,000 shares of Nevro stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $110.00, for a total value of $110,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew H. Galligan sold 12,000 shares of Nevro stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $110.39, for a total value of $1,324,680.00. The disclosure for this sale can be found here. Insiders have sold a total of 33,322 shares of company stock worth $3,538,891 over the last 90 days. Insiders own 7.60% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD boosted its holdings in Nevro by 91.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,078,635 shares of the medical equipment provider’s stock worth $199,588,000 after buying an additional 1,470,807 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Nevro by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 2,670,677 shares of the medical equipment provider’s stock worth $173,140,000 after buying an additional 102,183 shares during the last quarter. BlackRock Inc. boosted its holdings in Nevro by 1.2% in the 2nd quarter. BlackRock Inc. now owns 2,583,530 shares of the medical equipment provider’s stock worth $167,491,000 after buying an additional 29,637 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in Nevro by 11.7% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 2,067,400 shares of the medical equipment provider’s stock worth $134,029,000 after buying an additional 216,680 shares during the last quarter. Finally, Invesco Ltd. boosted its holdings in Nevro by 316.2% in the 2nd quarter. Invesco Ltd. now owns 1,970,969 shares of the medical equipment provider’s stock worth $127,778,000 after buying an additional 1,497,455 shares during the last quarter.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Story: What are the advantages to having securities held in street name?

Analyst Recommendations for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.